Viewing Study NCT05066035

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:09 PM
Ignite Modification Date: 2026-02-24 @ 2:09 PM
Study NCT ID: NCT05066035
Status: COMPLETED
Last Update Posted: 2021-10-04
First Post: 2021-09-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine
Sponsor: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neuromuscular Blockade View
None Sugammadex View
None Neostigmine View
None Complication of Anesthesia View
None Postoperative Residual Curarization View
None Rocuronium View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Residual Curarization View
None Postoperative View
None Complication View
None Neuromuscular blockade View
None Neostigmine View
None Sugammadex View
None Rocuronium View